BTX A51
Alternative Names: BTX-A51; PHM®-A51 PROTACsLatest Information Update: 28 Jul 2024
At a glance
- Originator Hebrew University of Jerusalem
- Developer BioTheryX; Edgewood Oncology
- Class Amines; Antineoplastics; Chlorinated hydrocarbons; Cyclohexanes; Cyclopropanes; Pyrazoles; Pyrimidines; Small molecules
- Mechanism of Action Casein kinase I inhibitors; Cyclin-dependent kinase 9 inhibitors; Cyclin-dependent kinase-activating kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Acute myeloid leukaemia; Breast cancer
- Preclinical Liposarcoma
- No development reported Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Solid tumours
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for phase-I development in Non-Hodgkin's-lymphoma(Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO)
- 28 Jul 2024 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO)
- 21 May 2024 Phase-II clinical trials in Breast cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT04872166)